Vivesto AB (FRA:OMA) Beta: 5.9493 (As of Jul. 03, 2026)


FRA:OMA Vivesto AB FRA:OMA
33 GF Score
Price €0.70
! 1 Warning Sign
View Full Analysis

What is Vivesto AB Beta?

Vivesto AB FRA:OMA -1.68% 33 Beta is 5.9493 as of Jul. 03, 2026. GuruFocus rates FRA:OMA with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-03), Vivesto AB's Beta is 5.9493.


Vivesto AB  (FRA:OMA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Vivesto AB Beta Related Terms


Vivesto AB Beta Historical Data

* Premium members only.

The historical data trend for Vivesto AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivesto AB Beta Chart

Vivesto AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 2.12 2.18 3.07

Vivesto AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.19 2.43 3.11 3.07 2.27

FRA:OMA vs ZTS, UTHR, VTRS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Beta distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Beta falls into.


FRA:OMA
33GF Score
Vivesto AB FRA:OMA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivesto AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 5.9493 mean?
Vivesto AB (FRA:OMA) has a Beta of 5.9493 as of Jul. 03, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Vivesto AB and its competitors.
Is Vivesto AB's Beta too high?
Vivesto AB's current Beta is 5.9493. Overall, Vivesto AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Beta compare to ZTS and UTHR?
Vivesto AB's Beta of 5.9493 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Vivesto AB and its competitors. Vivesto AB's current Beta is 5.9493. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (FRA:OMA) has a current Beta of 5.9493. The current Beta is 5.9493. Vivesto AB's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Vivesto AB (FRA:OMA), the current Beta is 5.9493 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Other Exchanges VIVE:Sweden
Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
33GF Score

Get the complete analysis for FRA:OMA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.70
Price